Vigil Neuroscience, Inc. Stock

Equities

VIGL

US92673K1088

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-05-17 EDT 5-day change 1st Jan Change
3.52 USD -0.56% Intraday chart for Vigil Neuroscience, Inc. +10.69% +4.14%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * - Sales 2025 * 329K 448K Capitalization 132M 180M
Net income 2024 * -86M -117M Net income 2025 * -105M -143M EV / Sales 2024 * -
Net cash position 2024 * 113M 154M Net cash position 2025 * 241M 328M EV / Sales 2025 * -330 x
P/E ratio 2024 *
-1.84 x
P/E ratio 2025 *
-1.83 x
Employees 65
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.79%
More Fundamentals * Assessed data
Dynamic Chart
Vigil Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Vigil Neuroscience, Inc. Presents Key Findings from Illuminate & Ignite Studies in ALSP At the 2024 American Academy of Neurology Annual Meeting CI
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating MT
Vigil Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vigil Neuroscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Markets Steady -2- DJ
Vigil Neuroscience Names Petra Kaufmann Chief Medical Officer MT
Vigil Neuroscience, Inc. Announces Executive Changes CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Vigil Neuroscience, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM
North American Morning Briefing : S&P 500 Futures -2- DJ
Morgan Stanley Downgrades Vigil Neuroscience to Underweight From Equalweight, Cuts Price Target to $4 From $13 MT
Vigil Neuroscience Reports Positive Interm Results for Treatment of Axonal Spheroids and Pigmented Glia MT
Transcript : Vigil Neuroscience, Inc. - Special Call
Vigil Neuroscience, Inc. Reports Positive Interim Data from Phase 2 Ignite Proof-Of-Concept Clinical Trial Evaluating Iluzanebart as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE CI
More news
1 day-0.56%
1 week+10.69%
Current month+34.87%
1 month+24.82%
3 months+16.17%
6 months-12.00%
Current year+4.14%
More quotes
1 week
3.28
Extreme 3.28
3.78
1 month
2.50
Extreme 2.5
3.85
Current year
2.50
Extreme 2.5
3.85
1 year
2.50
Extreme 2.5
11.11
3 years
2.18
Extreme 2.18
18.27
5 years
2.18
Extreme 2.18
18.27
10 years
2.18
Extreme 2.18
18.27
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 20-06-30
Director of Finance/CFO 50 20-06-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 55 20-06-30
Director/Board Member 64 22-04-17
Director/Board Member 59 20-10-31
More insiders
Date Price Change Volume
24-05-17 3.52 -0.56% 49,336
24-05-16 3.54 +1.58% 32,182
24-05-15 3.485 -4.78% 52,802
24-05-14 3.66 +0.27% 55,190
24-05-13 3.65 +14.78% 649,640

Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm

More quotes
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.52 USD
Average target price
16.75 USD
Spread / Average Target
+375.85%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW